Видео ютуба по тегу Arid1A

ARID1A
ARID1A
Molecular phenotyping of ARID1A-deficient gastric cancer reveals therapeutic opportunities
Molecular phenotyping of ARID1A-deficient gastric cancer reveals therapeutic opportunities
Molecular Tumor Board - Thoracic ARID1A and PD-L1 present
Molecular Tumor Board - Thoracic ARID1A and PD-L1 present
ARID1A deficiency linked to metastasis, chemoresistance of lung cancer cells
ARID1A deficiency linked to metastasis, chemoresistance of lung cancer cells
ICRN Webinar: ARID1A and CCA
ICRN Webinar: ARID1A and CCA
Marco Trizzino:
Marco Trizzino: "Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from ..."
Altered ARID1A expression in colorectal cancer
Altered ARID1A expression in colorectal cancer
Low ARID1A expression improves the response to immunotherapy in EGFR-mutant lung adenocarcinoma
Low ARID1A expression improves the response to immunotherapy in EGFR-mutant lung adenocarcinoma
ARID1A determines luminal identity & therapeutic response in ER+ breast cancer; by Guotai Xu, MSKCC
ARID1A determines luminal identity & therapeutic response in ER+ breast cancer; by Guotai Xu, MSKCC
Altered ARID1A expression in colorectal cancer
Altered ARID1A expression in colorectal cancer
This 30s Trick KOs ARID1A-Mutant GEP-NEC #sciencefather #ARID1A
This 30s Trick KOs ARID1A-Mutant GEP-NEC #sciencefather #ARID1A
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
ARID1A AT Rich Interactive Domain 1A
ARID1A AT Rich Interactive Domain 1A
AC21 - Sarinya Kongpetch: Novel Genomic Opportunities- BAP1, CDK, ARID1A
AC21 - Sarinya Kongpetch: Novel Genomic Opportunities- BAP1, CDK, ARID1A
RETRACTED ARTICLE: BCORL1 is an independent prognostic marker and contributes to cell... | RTCL.TV
RETRACTED ARTICLE: BCORL1 is an independent prognostic marker and contributes to cell... | RTCL.TV
Gene Music using Protein Sequence of ARID1A
Gene Music using Protein Sequence of ARID1A "AT RICH INTERACTIVE DOMAIN 1A (SWI-LIKE)"
Saravana Selvanathan, Ph.D., Georgetown Lombardi Comprehensive Cancer Center
Saravana Selvanathan, Ph.D., Georgetown Lombardi Comprehensive Cancer Center
MGE Video Presentation - Alice Cross
MGE Video Presentation - Alice Cross
Transcriptional-translational conflict -a novel tumor suppressive mechanism
Transcriptional-translational conflict -a novel tumor suppressive mechanism
Synthetic Lethality Between ARID1A Loss and EZH2 Inhibition in Ovarian Clear Cell Carcinoma
Synthetic Lethality Between ARID1A Loss and EZH2 Inhibition in Ovarian Clear Cell Carcinoma